<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01825317</url>
  </required_header>
  <id_info>
    <org_study_id>NRX-KOR1</org_study_id>
    <nct_id>NCT01825317</nct_id>
  </id_info>
  <brief_title>Effect of NeuroAD on Alzheimer Patients</brief_title>
  <official_title>Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuronix Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>company: K The Power</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Neuronix Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-invasive stimulation of the brain using magnetic and cognitive stimulation by computer
      for the treatment of Alzheimer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Synchronized TMS and cognitive training for the treatment of mild to moderate Alzheimer's
      patients. Treatment is delivered 5 days a week, for 6 weeks, visit is about an hour long.

      Evaluation is by neuropsychological evaluation at 6 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ADAS-Cog</measure>
    <time_frame>6 weeks</time_frame>
    <description>Alzheimer's disease assessment scale - cognitive test</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>NeuroAD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment by the NeuroAD device, real treatment by synchronized TMS+cognitive training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham NeuroAD</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham TMS+cog, has the same sound and appearance, patients come for the same number of treatments and are exposed to the same procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NeuroAD</intervention_name>
    <description>synchronized TMS+COGNITIVE TRAINING</description>
    <arm_group_label>NeuroAD</arm_group_label>
    <other_name>NICE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham device</intervention_name>
    <description>Sham TMS+cog, has the same sound and appearance as the real device, delivers no energy.</description>
    <arm_group_label>Sham NeuroAD</arm_group_label>
    <other_name>Control device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female age 60-90 years

          2. Patients diagnosed with mild or moderate stage of Alzheimer's Disease, according to
             the DSM-IV criteria.

          3. MMSE score 18 to 26

          4. Adas-cog above 17

          5. Physically acceptable for the study as confirmed by medical history and exam.

          6. Spouse, family member or professional caregiver agree and capable of taking care and
             be responsible for the participation of the patient in the study (answering questions
             regarding the patient's condition and assuming responsibility for medication)

          7. Agreement to participate in approximately 14 weeks during the study.

          8. Normal or corrected to normal ability to see and to hear.

          9. Korean as primary language

         10. 8th grade education minimum

        Exclusion Criteria:

          1. CDR 0 or 3

          2. Severe agitation;

          3. Mental retardation;

          4. Patient lacking capacity to consent to study participation

          5. Unstable medical condition;

          6. Use of benzodiazepines or barbiturates during the study and preceding two weeks;

          7. Pharmacological immunosuppression;

          8. Participation in a clinical trial with any investigational agent within two weeks
             prior to study enrollment;

          9. History of Epileptic Seizures or Epilepsy;

         10. Contraindication for performing MRI scanning;

         11. Contraindication for receiving TMS treatment according to a TMS questionnaire;

         12. Pregnant women, and women who have the ability to become pregnant unless they are on
             an acceptable method of contraception during the study.

         13. Patients with personal history of any clinically defined neurological disorder,
             including organic brain disease, epilepsy, stroke, brain lesions, or multiple
             sclerosis; or personal history of previous neurosurgery or head trauma that resulted
             in loss of consciousness.

         14. Patients with depression, bipolar disorder or psychotic disorders or any other
             neurological or psychiatric condition (whether now or in the past), which the
             Investigator finds as interfering with the study

         15. Alcoholism or drug addiction as defined by DSM-IV within last 5 years (addicted more
             than one year and or in remission less than 3 years) or severe sleep deprivation

         16. Patients treated with cholinesterase inhibitors, or memantine or Ginko-biloba will be
             allowed to participate, if the treatment has started at least 6 months previous to
             recruitment. The patients should keep their dose of medication during the whole trial
             as prior to study begin.

         17. Patients with metal in the head, except the mouth (i.e. cochlear implants, implanted
             brain stimulators, aneurysm clips)

         18. Patients with increased intracranial pressure

         19. Cardiac pacemakers

         20. Implanted neurostimulators

         21. Implanted medication pumps

         22. Intracardiac lines

         23. Significant heart disease

         24. Currently taking medication that lower the seizure threshold

         25. Significant sleep deprivation and alcoholism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chungnam national university hospital, Daejeon Geriatric Medical Center</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2013</study_first_submitted>
  <study_first_submitted_qc>April 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2013</study_first_posted>
  <last_update_submitted>April 17, 2014</last_update_submitted>
  <last_update_submitted_qc>April 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>TMS</keyword>
  <keyword>NeuroAd</keyword>
  <keyword>cognitive training</keyword>
  <keyword>ADAS-Cog</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

